# A Study to Evaluate CSJ148 in Pregnant Women With Primary HCMV Infection

> **NCT03369912** · PHASE2 · WITHDRAWN · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- HCMV Infection

## Interventions

- **BIOLOGICAL:** CSJ148
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03369912
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-10-23
- **Primary completion:** 2022-11-15
- **Final completion:** 2022-11-15
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Company decision to withdraw before study started
- **Last updated:** 2018-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03369912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03369912, "A Study to Evaluate CSJ148 in Pregnant Women With Primary HCMV Infection". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03369912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*